Safety Update – product information updates
When new safety information comes to light about medicinal products, Swissmedic works closely with marketing authorisation holders to update the corresponding product information (Information for healthcare professionals and Patient information). As a result, healthcare professionals gain timely access to safety-related findings.
The following overview is updated monthly and provides information about selected active substances or active substance groups whose Information for healthcare professionals has been, or will be, updated with new safety-related information.
These updates are currently available in German, French, or Italian.
Important information
The updates to product information for generics are delayed as these are adapted at a later date to those of the original product. Please note that this is not a complete overview since not all changes to individual Information for healthcare professionals are presented in detail, and the safety information listed for individual medicinal products containing an active substance or substance class may already be included in the Information for healthcare professionals.
The information is subject to possible legal remedies. In all cases, the current versions of the Information for healthcare professionals available at www.swissmedicinfo-pro.ch are binding.
All Safety Updates since November 2025
Safety of medicines – always up to date
Subscribe to the newsletter
The “Safety of medicines” newsletter provides monthly updates on the most important revisions to the product information for selected active substances or substance groups.
| Wirkstoff(e) |
Neue Sicherheitsinformation |
Angepasste Rubrik(en) |
(D)HPC |
| Bevacizumab |
Hyaline occlusive glomerular microangiopathy |
Undesirable effects |
– |
| Burosumab |
Risk of severe hypercalcaemia: Monitoring of serum calcium and parathyroid hormone levels; do not administer in cases of moderate to severe hypercalcaemia |
Dosage/use, Warnings and precautions, Undesirable effects |
DHPC – Crysvita (Burosumab) |
| Capecitabine |
Enteritis, ascites, lower abdominal pain, gastro-oesophageal reflux, blood in stool |
Undesirable effects |
– |
| Datopotamab deruxtecan |
Hypersensitivity / anaphylactic reaction: Have emergency equipment available.In case of severe reactions, permanently discontinue treatment immediately. |
Warnings and precautions Undesirable effects |
– |
| Growth hormones |
Slipped capital femoral epiphyses, osteonecrosis of the femoral head (incl. Legg-Calvé-Perthes disease): Clinical orthopaedic examination and immediate interruption of treatment in case of persistent hip/knee pain and/or limping. Resume treatment only with the agreement of the specialist. |
Warnings and precautions, Undesirable effects |
– |
| Guanfacine |
Blurred vision |
Undesirable effects |
– |
| Lorlatinib |
Women of childbearing age: Use highly effective non-hormonal contraceptive methods for at least 35 days after completing therapy. |
Warnings and precautions, Pregnancy, lactation |
– |
| Platinum-based cytostatics |
Passes into breast milk |
Pregnancy, lactation |
– |
| Sulfasalazine |
Anaphylaxis |
Undesirable effects |
– |
